home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.69 +0.95 (+2.33%)

Official Closing Price Updated: 4:15 PM EST, Mar 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

These 7 Biotech Stocks Are Set to Boom in 2023 ↗

October 10, 2022

This article looks at seven biotech stocks that look like good options to move significantly higher in 2023

Via InvestorPlace

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

October 04, 2022

From Exelixis, Inc.

Via Business Wire

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer ↗

September 08, 2022

Via Benzinga

Recap: Exelixis Q2 Earnings ↗

August 09, 2022

Exelixis (NASDAQ:EXEL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Exelixis Handily Beats Second-Quarter Expectations, Retains 2022 Outlook ↗

August 09, 2022

Exelixis stock was flat immediately after the earnings release.

Via Investor's Business Daily

Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients ↗

September 12, 2022

Via Benzinga

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

September 10, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

September 07, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis-BioInvent Establish Immuno-Oncology Pact ↗

June 16, 2022

Via Benzinga

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September

September 06, 2022

From Exelixis, Inc.

Via Business Wire

Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗

August 12, 2022

The major indexes continued to advance, despite some key warnings.

Via Investor's Business Daily

Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 09, 2022

From Exelixis, Inc.

Via Business Wire

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

July 26, 2022

From Exelixis, Inc.

Via Business Wire

7 Undervalued Biotech Stocks to Buy Before They Boom ↗

July 25, 2022

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

Via InvestorPlace

Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer

July 11, 2022

From Exelixis, Inc.

Via Business Wire

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill ↗

July 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

July 07, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference

July 05, 2022

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗

June 24, 2022

Upgrades

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

June 21, 2022

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

June 16, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June

May 31, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022

May 26, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

May 26, 2022

From Exelixis, Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ↗

May 24, 2022

Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!

Via InvestorPlace

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com